|
HEALTH POLICY |
|
Health Outcomes
Presentations |
PHP1 |
AN ANALYSIS OF A
HEALTHY START SMOKING CESSATION PROGRAM
Mayhew DY1, Perrin KM2, Struchen W3, 1University of Florida,
Gainesville, FL, USA; 2University of South Florida, Tampa, FL, USA; 3Florida
Department of Health, St. Petersburg, FL, USA |
| PHP2 |
THE EFFECT OF
PREFERRED DRUG STATUS ON PATIENT SWITCHING, ADHERENCE, AND DAYS OF THERAPY
Hutchison S, Miller T, AdvancePCS, Scottsdale, AZ, USA |
| PHP3 |
ASSESSING FRACTURE
RISK WITH PRESCRIPTION DRUGS IN MEDICARE-ELIGIBLE PLAN MEMBERS OF A
TELECOMMUNICATIONS COMPANY
Erwin G1, Kleinman N2, Astuto J3, Gardner H2, Lipson L4,
Stuart B5, Wilson P6, 1Omnicare, King of Prussia, PA, USA; 2Options &
Choices, Inc, Cheyenne, WY, USA; 3Verizon Communications, Alpharetta, GA,
USA; 4University of Southern California School of Medicine, Los Angeles, CA,
USA; 5University of Maryland, Baltimore, MD, USA; 6Associates & Wilson,
Rosemont, PA, USA |
| PHP4 |
GENERIC NARROW
THERAPEUTIC INDEX DRUG USE: 1996-1998
Chao J, Taylor SD, McKercher PL, Kirking DM, University of Michigan,
Ann Arbor, MI, USA |
| PHP5 |
IMPACT OF
MULTI-TIERED PHARMACY BENEFITS ON MEDICATION ADHERENCE
Valuck RJ1, Nair K1, Wolfe P2, McCollum M1, Lewis S3, 1University of
Colorado School of Pharmacy, Denver, CO, USA; 2Wolfe Statistical Consulting,
LLC, Denver, CO, USA; 3Anthem Blue Cross Blue Shield of Colorado, Denver,
CO, USA |
| PHP6 |
AN ANALYSIS OF THE
EFFECT OF MANAGED CARE IMPLEMENTATION ON PRESCRIPTION DRUG UTILIZATION BY
TEXAS MEDICAID CLIENTS
Richards KM, University of Texas, Austin, TX, USA |
| PHP7 |
HORIZONTAL INEQUITY
IN HEALTH CARE UTILIZATION IN JAPAN
Honda C1, Ohkusa Y2, 1Yao Health Center, Osaka Prefecture, Ibaragi,
Osaka, Japan; 2Osaka University, Ibaragi, Osaka, Japan |
| PHP8 |
PHP8 PERCEPTIONS OF COUNSELING
FOR OBESITY AND RELATED BARRIERS AMONG COMMUNITY PHARMACISTS IN TEXAS
Dastani HB1, Brown CM1, O'Donnell D2, 1University of Texas at Austin,
Austin, TX, USA; 2Roche Pharmaceuticals, Austin, TX, USA |
| PHP9 |
STRATEGIES TO REDUCE
PREVENTABLE DRUG-RELATED MORBIDITY
Flanagan PS1, MacKinnon NJ1, Hanlon NT2, Robertson HA1, 1Dalhousie
University, Halifax, Nova Scotia, Canada; 2University of Northern British
Columbia, Prince George, British Columbia, Canada |
| PHP10 |
USE OF HEALTH
OUTCOMES DATA IN PROMOTIONAL MATERIALS
Harris SD1, Bryant-Comstock L2, 1GlaxoSmithKline, Global Health
Outcomes Dept, RTP, NC & University of North Carolina at Chapel Hill, Chapel
Hill, NC, USA; 2GlaxoSmithKline, Global Health Outcomes Dept, Research
Triangle Park, NC, USA |
| PHP11 |
A DESCRIPTION OF
DISCARDED PRESCRIPTION DRUGS
Tennyson DH, Auburn University, Auburn, AL, USA |
| PHP12 |
CHANGING DRUG
SELLER BEHAVIOR ON CHILD DIARRHEA MANAGEMENT: EFFECTIVENESS OF TRAINING
PROGRAM AND IMPLICATIONS OF KNOWLEDGE-PRACTICE GAP
Ratanawijitrasin S1, Panyawuthikrai P1, Suttajit S1, Hongsamoot D2,
1Chulalongkorn University, Bangkok, Thailand; 2Food and Drug Administration,
Nonthaburi, Thailand |
| PHP13 |
THE ROLE OF VARIOUS
FACTORS IN THE DRUG FORMULARY DECISION-MAKING PROCESS
MacKinnon NJ, Kumar R, Chaudhary DAN, Dalhousie University,
Halifax, NS, Canada |
| PHP14 |
IMPACT OF
MULTI-TIERED PHARMACY BENEFITS ON PATIENT ATTITUDES AND BEHAVIOR
Nair KV1, Wolfe P2, Ganther JM3, Valuck RV2, Mccollum M1, Lewis SJ4,
1University of Colorado Health Sciences Center, School of Pharmacy, Denver,
CO, USA; 2Wolfe Statistical Consulting, LLC, Denver, CO, USA; 3University of
Iowa, Iowa City, IA, USA; 4Anthem Blue Cross Blue Shield of Colorado,
Denver, CO, USA |
| PHP15 |
SURVIVAL RATES FOR
PATIENTS RECEIVING TRANSFUSIONS IN THE UNITED STATES FROM AN ADMINISTRATIVE
MANAGED CARE DATABASE
Grima D1, Marshall D1, Kleinman S2, AuBuchon J3, Kulin N1, Cheng R4,
1Innovus Research Inc, Burlington, ON, Canada; 2Kleinman Biomedical
Research, Victoria, BC, Canada; 3Dartmouth-Hitchcock Medical Centre,
Lebanon, NH, USA; 4Protocare Sciences Inc, Santa Monica, CA, USA |
| PHP16 |
PATIENT SATISFACTION
AND PHARMACEUTICAL OUTPATIENT CARE
Huttin CC, University of Paris, Paris, France and EIASM, Brussels,
Belgium |
| PHP17 |
DRUG INSURANCE TYPE
AND INAPPROPRIATE PRESCRIPTIONS FOR THE ELDERLY: ANY CONNECTIONS?
Liu GG, Fu AZ, University of North Carolina at Chapel Hill, Chapel
Hill, NC, USA |
| PHP18 |
STOP: SMOKING
CESSATION TARGET: OBSERVATORY PROGRAM, THE FRENCH PHYSICIAN’S PROGRESS
Taieb C, Myon E, PharmacoEconomics Programs, bioMérieux-Pierre Fabre,
Boulogne Billancourt, France |
| PHP19 |
MEDICATION SUPPORT
PROGRAM IMPROVES MEDICATION COMPLIANCE
Taitel MS, Frick J, Herman P, Kurcz L, Smith S, First Health, Downers
Grove, IL, USA |
| PHP20 |
SURVIVAL ANALYSIS IN
SEDATED INTENSIVE CARE UNIT (ICU) PATIENTS
Chaikledkaew U1, Hopefl AW2, Kamath TV3, Johnson KA1, 1University of
Southern California, Los Angeles, CA, USA; 2AmeriNet, St. Louis, MO, USA;
3Bristol-Myers Squibb Company, Princeton, NJ, USA |
| PHP21 |
THERAPEUTIC
INTERCHANGEABILITY OF LEVOTHYROXINE
von Scheele B, Sherrill B, Gilsenan AW, Richter A, Devlin P, RTI
Health Solutions, Research Triangle Park, NC, USA |
|
Economic Outcomes Presentations |
| PHP22 |
USING THE AMERICAN
PRODUCTIVITY AUDIT (APA) TO INFORM EMPLOYERS ABOUT THE WORK-RELATED COST OF
HEALTH CONDITIONS IN THEIR WORKFORCE
Matousek DM, Ricci J, Stewart W, Chee E, AdvancePCS, Center for Work
& Health, Hunt Valley, MD, USA |
| PHP23 |
PREVENTABLE
DRUG-RELATED MORBIDITY AND MORTALITY IN OLDER ADULTS: A CANADIAN
COST-OF-ILLNESS MODEL
Kidney T, MacKinnon NJ, Dalhousie University, Halifax, NS, Canada |
| PHP24 |
PHARMACY BENEFIT
RESOURCE UTILIZATION BY ENROLLEES OF A PUBLIC EMPLOYEES INDEMNITY INSURANCE
PROGRAM FOR FIVE FISCAL YEARS FROM 1996 TO 2001
Jacobs EW, Bui TT, Jenkins TL, Park A, Univeristy of Oklahoma,
Oklahoma City, OK, USA |
| PHP25 |
WORK-RELATED COST
OF EPISODIC AND CHRONIC-EPISODIC HEALTH CONDITIONS IN THE UNITED STATES:
RESULTS FROM THE AMERICAN PRODUCTIVITY AUDIT
Ricci J1, Chee E1, Morganstein D2, 1AdvancePCS, Center for Work and
Health, Hunt Valley, MD, USA; 2Westat, Rockville, MD, USA |
| PHP26 |
COST-EFFECTIVENESS
OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR
HEPATITIS B
VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)
Grima D1, Marshall D1, Weinstein M2, Wong J3, Kleinman S4, AuBuchon
J5, 1Innovus Research Inc, Burlington, ON, Canada; 2Harvard School of Public
Health, Boston, MA, USA; 3New England Medical Center, Boston, MA, USA;
4Kleinman Biomedical Research, Victoria, BC, Canada; 5Dartmouth-Hitchcock
Medical Centre, Lebanon, NH, USA |
| PHP27 |
IMPACT OF A 3-TIER
PHARMACY BENEFIT ON UTILIZATION PATTERNS OF TOP 10 THERAPEUTIC CLASSES: A
15-MONTH FOLLOW-UP STUDY
Ara S, Yu W, WellPoint Pharmacy Management, West Hills, CA, USA |
| PHP28 |
INTER-INSTITUTIONAL
VARIABILITY IN PHARMACY COSTS, LENGTH OF STAY AND MORTALITY ASSOCIATED WITH
CARDIAC TRANSPLANTATION AT ACADEMIC HEALTH CENTERS: A RETROSPECTIVE DATABASE
ANALYSIS
Korner EJ, Weber LA, Matuszewski KA, University HealthSystem
Consortium, Chicago, IL, USA |
| PHP29 |
EVALUATION OF DRUGS
IN A THREE-TIER PRESCRIPTION DRUG BENEFIT CO-PAYMENT PRICING STRUCTURE
Patel G, Shah S, Siganga W, Lively B, Holiday-Goodman M, The
University of Toledo, Toledo, OH, USA |
| PHP30 |
PRACTICAL ASPECTS OF
DESIGNING AND CONDUCTING PHARMACOECONOMIC STUDIES IN JAPAN
Doherty J, Sato K, Pharmacia Inc, Tokyo, Japan |
| PHP31 |
OUTCOMES AND COSTS
OF ACUTE TREATMENT OF TRAUMATIC BRAIN INJURY
McGarry L1, Thompson D1, Millham FH2, Cowell L3, Snyder PJ4,
Lenderking W4, Weinstein MC5, 1Innovus Research, Inc, Medford, MA, USA;
2Boston Medical Center, Boston, MA, USA; 3Center for Neurological Recovery,
Newton Centre, MA, USA; 4Pfizer Global Research & Development, Groton, CT,
USA; 5Harvard School of Public Health, Boston, MA, USA |
| PHP32 |
PATIENT WILLINGNESS
TO PAY FOR COGNITIVE PHARMACY SERVICES IN AMBULATORY CARE SETTINGS
Olagundoye A, Daftary MN, Dutta A, Wakijra C,
Howard University, Washington, DC, USA |
| PHP33 |
POLISH GUIDELINES
FOR CONDUCTING BUDGET IMPACT ANALYSIS IN THEIR COMPARISON TO EXISTING
GUIDANCE ON BUDGET IMPACT ANALYSIS IN OTHER COUNTRIES
Orlewska E1, Mierzejewski P2, Kanavos P3, 1Medical University of
Warsaw, Warsaw, Poland; 2Ministry of Health, Warsaw, Poland; 3Harvard
University Medical School, Boston, MA, USA |
| PHP34 |
ECONOMICS OF
TRANSFUSION
Yeh JM1, Botteman MF2, Pashos CL1, Postma MJ3, Staginnus U4, 1Abt
Associates Clinical Trials, Cambridge, MA, USA; 2Abt Associates Clinical
Trials, Bethesda, MD, USA; 3Groningen University, Groningen, Netherlands;
4Baxter, S.L, Madrid, Spain |
| PHP35 |
ANALYZING THE
CLINICAL, ECONOMIC, AND POLICY IMPACT OF INDIVIDUALIZED MEDICINE BASED ON
GENETIC INFORMATION ("PHARMACOGENOMICS")
Phillips KA1, Veenstra DL2, Oren E1, Lee JK1, Sadee W1, 1University
of California, San Francisco, San Francisco, CA, USA; 2University of
Washington, Seattle, WA, USA |
| PHP36 |
COST EFFECTIVENESS
ANALYSIS OF PHARMACEUTICAL CARE IN A MEDICARE DRUG BENEFIT PROGRAM
Etemad LR, Hay JW, University of Southern California, Los Angeles,
CA, USA |
| PHP37 |
GENERIC PRESCRIBING
INDEX: A TOOL TO PROMOTE COST-EFFECTIVE PRESCRIBING
West D1, Golden WE1, Robert H1, Wells C2, Sanchez N2, 1University of
Arkansas for Medical Sciences, Little Rock, AR, USA; 2Arkansas Foundation
for Medical Care, Little Rock, AR, USA |
| PHP38 |
IMPACT OF SELECTED
CONDITIONS ON THE COSTS OF ACCIDENTS AND INJURIES
Ollendorf DA, Peterson AN, Jilinskaia E, PharMetrics Inc, Watertown,
MA, USA |
| PHP39 |
IMPACT OF AN
INCREASE IN PRESCRIPTION CO-PAYMENT ON DRUG UTILIZATION
Meissner BL1, Moore WM1, Shinogle JA1, Reeder CE1, Little JM2,
1University of South Carolina, Columbia, SC, USA; 2Companion HealthCare,
Columbia, SC, USA |
| PHP40 |
COST EFFECTIVENESS
OF PATHOGEN INACTIVATION IN PLATELET TRANSFUSIONS
Bell C1, Weissfeld J2, Botteman M1, Gregory D3, Staginnus U4, Pashos
C5, 1Abt Associates Clinical Trials, Bethesda, MD, USA; 2University of
Pittsburgh, Pittsburgh, PA, USA; 3Baxter, Fenwal, Roundlake, IL, USA;
4Baxter, Fenwal Europe, Madrid, Spain; 5Abt Associates Clinical Trials,
Cambridge, MA, USA |
| PHP41 |
VALUE OF VACCINATION
Ehreth J, Aventis Pasteur, Lyon, France |
| PHP42 |
AN EPIDEMIOLOGICAL
EXAMINATION OF MEDICATION RESOURCE USE AND COSTS AMONG THE INSURED ELDERLY
Alemayehu B, Aubert RE, Epstein R, Merck-Medco Managed Care, LLC,
Franklin Lakes, NJ, USA |
| PHP43 |
FACTORS ASSOCIATED
WITH OUT-OF-POCKET PRESCRIPTION DRUG COSTS
Kumar RN, Taylor SD, Mckercher PL, University of Michigan, Ann Arbor,
MI, USA |
| PHP44 |
HOW MUCH DOES IT
COST TO DIE OF THAT? EFFECTS OF
AGE AND CHRONIC ILLNESS ON HEALTHCARE COSTS AT THE END OF LIFE
Mapel DW, Frost FJ, Paine S, Hurley JS, Petersen HV, Lovelace
Respiratory Research Institute, Albuquerque, NM, USA |
| PHP45 |
A DECISION ANALYSIS
MODEL FOR SCREENING OF HEREDITARY HEMOCHROMATOSIS
Greenwood TG, The Ohio State University, Columbus, OH, USA |
| PHP46 |
A COST-BENEFIT
ANALYSIS OF AN INPATIENT, PHARMACY-MANAGED MEDICATION ASSISTANCE PROGRAM FOR
INDIGENT PATIENTS: A 3-MONTH PILOT STUDY
Coleman CI1, Reddy P1, Quercia RA2, Gousse G2, 1University of
Connecticut, Storrs, CT, USA; 2Hartford Hospital, Hartford, CT, USA
|
| PHP47 |
CHILDREN IN NEED OF
PHARMACARE: ANALYSIS OF MEDICATION FUNDING REQUESTS AT THE TORONTO HOSPITAL
FOR SICK CHILDREN
Ungar WJ1, Daniels C2, McNeill T2, Seyed M1, 1The Hospital for Sick
Children Research Institute, Toronto, ON, Canada; 2The Hospital for Sick
Children, Toronto, ON, Canada |
| PHP48 |
COST SENSITIVENESS
AND PHYSICIAN TREATMENT CHOICES
Huttin CC, Evaluation Network of Drug European Policy (Virtual Think
Tank), Brussels, Belgium |
|
Quality of Life Presentations |
| PHP49 |
WITHDRAWN |
| PHP50 |
HEALTH-RELATED
QUALITY OF LIFE IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE: MEASUREMENT
PROPERTIES OF THE HEALTH UTILITIES INDEX
Horsman JR, Furlong W, Barr RD, Sek J, Pai M, Walker I, McMaster
University, Hamilton, ON, Canada |
| PHP51 |
IMPROVED QUALITY OF
LIFE AND DECREASED USE OF HEALTHCARE RESOURCES ARE MAINTAINED DURING 3 YEARS
OF GROWTH HORMONE (GH) SUBSTITUTION IN HYPOPITUITARY ADULTS WITH GH
DEFICIENCY
Rosén T1, Johannsson G1, Mattsson A2, Koltowska M2, Svensson J1,
Wirén L1, Götherström G1, Bengtsson BÅ1, 1Research Centre for Endocrinology
and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden; 2KIGS/KIMS
Outcomes Research, Pharmacia AB, Stockholm, Sweden |
| PHP52 |
A RANDOMIZED,
OPEN-LABEL PREFERENCE STUDY OF GENGRAF® COMPARED TO NEORAL® IN STABLE
SOLID-ORGAN TRANSPLANT RECIPIENTS
Steinberg S1, Venuto R2, Kuruvila KC3, Taylor D4, Anil Kumar MS5, First MR6,
Greco R7, Boodhoo TI7, Singh A7, Ashraf T7, Japour AJ7, Ryan J7,
1Balboa Nephrology Medical Group, San Diego, CA, USA; 2Erie County Medical
Center, Buffalo, NY, USA; 3South Denver Nephrology Associates, Denver, CO,
USA; 4Cleveland Clinic Foundation, Cleveland, OH, USA; 5Hahnemann University
Hospital, Philadelphia, PA, USA; 6University Hospital, Cincinnati, OH, USA;
7Abbott Laboratories, Abbott Park, IL, USA |
| PHP53 |
STUDY OF SF-36V.2 IN
A MONTANA NATIVE AMERICAN POPULATION
Carter JT, The University of Montana, Missoula, MT, USA |
| PHP54 |
PREVENTABLE
DRUG-RELATED MORBIDITY IN OLDER ADULTS IN NOVA SCOTIA, CANADA: DEVELOPMENT
OF QUALITY INDICATORS
Robertson H, MacKinnon NJ, Tonks RS, Dalhousie University, Halifax,
NS, Canada |
| PHP55 |
CONTENT ANALYSIS OF
QUALITY OF LIFE AND PHARMACOECONOMIC MESSAGES IN PHARMACEUTICAL PRODUCT
ADVERTISEMENTS
Munch EA1, Stolshek B2, Grizzle AJ1, 1University of Arizona College
of Pharmacy, Tucson, AZ, USA; 2Amgen, Inc, Thousand Oaks, CA, USA |
|
CARDIOVASCULAR DISEASE/DISORDERS |
|
Clinical Outcomes Presentations |
| PCV1 |
EFFICACY OF
AMLODIPINE IN REDUCING SYSTOLIC BLOOD PRESSURE: A SYSTEMATIC REVIEW OF THE
LITERATURE
Levine CB, Frame D, Connelly JE, Ludensky V,
Privetera ML, Fahrbach KR, MetaWorks Inc, Medford, MA, USA |
| PCV2 |
ADVERSE EVENTS IN
CABG TRIALS: A SYSTEMATIC REVIEW AND ANALYSIS
Nalysnyk L1, Fahrbach KR1, Reynolds MW2, Zhao SZ2, Ross SD1,
1MetaWorks Inc, Medford, MA, USA; 2Pharmacia Corporation, Peapack, NJ, USA
|
| PCV3 |
A RETROSPECTIVE,
OBSERVATIONAL COHORT STUDY OF THE EFFECTS OF STATIN THERAPY ON LIPID LEVELS
IN A NATURALISTIC SETTING
Willey VJ1, Bullano MF1, Cziraky MJ1, Tran MH2, Corbelli JC3,
1Health Core, Newark, DE, USA; 2Pfizer, Inc, New York, NY, USA; 3Buffalo
Cardiology and Pulmonary Associates, Williamsville, NY, USA |
| PCV4 |
TRENDS IN THE
ATTAINMENT OF CHOLESTEROL TREATMENT GOALS: EVIDENCE FROM MANAGED CARE
Menzin J1, Brown J1, Friedman M1, Saperia G2, Boulanger L1, Tran M3,
1Boston Health Economics, Waltham, MA, USA; 2Fallon Clinic, Worcester, MA,
USA; 3Pfizer, Inc, New York, NY, USA |
| PCV5 |
ESTIMATING THE
IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES
Matchar DB, Samsa GP, Duke University, Durham, NC, USA |
| PCV6 |
IMPACT OF
PHARMACIST-MANAGED AMBULATORY LIPID CLINIC
Cross LB, University of Tennessee Health Sciences Center, Memphis,
TN, USA |
| PCV7 |
AN ANALYSIS OF
SCREENING RATES FOR HYPERLIPIDEMIA AMONG MANAGED CARE PLAN MEMBERS
PREVIOUSLY HOSPITALIZED FOR CORONARY HEART DISEASE
Ting D1, Gerthoffer T2, 1Pfizer Inc, Carrollton, TX, USA;
2Pfizer Inc, Plano, TX, USA |
| PCV8 |
CLINICAL AND
ECONOMIC IMPACTS OF PHARMACIST-MANAGED ANTICOAGULATION MONITORING SERVICES
Doan QD1, Godley PJ2, Shepherd MD1, Lawson KA1, Wilson JP1,
1University of Texas at Austin, Austin, TX, USA; 2Scott & White Memorial
Hospital, Temple, TX, USA |
| PCV9 |
ASSESSING RISK
REDUCTION AND NNT AMONG TYPE 2 DIABETICS TREATED WITH FIBRIC ACID
DERIVATIVES
Boening AJ, Phillips AL, Cifaldi M, Ashraf T, Abbott Laboratories,
Abbott Park, IL, USA |
| PCV10 |
BLOOD PRESSURE
REDUCTION AND GAINS IN LIFE
EXPECTANCY BASED UPON A MARKOV MODEL OF PRIMARY AND SECONDARY CARDIOVASCULAR
EVENTS
Sesso HD1, Chen RS2, L'Italien GJ3, Lapuerta P2, Lee WC4,
Paramore C4, Glynn RJ1, 1Brigham and Women's Hospital, Boston, MA, USA;
2Bristol-Myers Squibb, Princeton, NJ, USA; 3Bristol-Myers Squibb,
Wallingford, CT, USA; 4MEDTAP International, Bethesda, MD, USA |
|
Economic Outcomes Presentations |
| PCV11 |
THE COST OF WARFARIN
MONITORING IN ANTICOAGULATION CLINICS: A MULTI-SITE MANAGED CARE STUDY
Menzin J1, Boulanger L1, Hauch O2, Friedman M1, Marple C2, Wygant G2,
Hurley J3, Pezzella S4, Kaatz S5, 1Boston Health Economics, Waltham, MA,
USA; 2AstraZeneca, L.P, Wayne, PA, USA; 3Lovelace Respiratory Research
Institute, Albuquerque, NM, USA; 4Fallon Clinic, West Boylston, MA, USA;
5Henry Ford Clinic, Detroit, MI, USA |
| PCV12 |
IMPACT OF ATRIAL
FIBRILLATION ON RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH UNDERLYING
CARDIOVASCULAR DISEASES
Doshi JA1, Khandker RK2, Roth DA2, 1University of Maryland,
Baltimore, MD, USA; 2GlaxoSmithKline, Collegeville, PA, USA |
| PCV13 |
HOSPITAL TREATMENT
PATTERNS AND RESOURCE UTILIZATION IN CONGESTIVE HEART FAILURE PATIENTS
Blount AC, Gaylord-Miles B, Hatch V, Gutierrez B, Premier, Inc,
Charlotte, NC, USA |
| PCV14 |
COST-EFFECTIVENESS
OF THROMBOPROPHYLAXIS IN ACUTELY-ILL MEDICAL INPATIENTS
McGarry L1, Thompson D1, Goldhaber S2, Stokes M1, Weinstein
MC3, 1Innovus Research, Inc, Medford, MA, USA; 2Brigham & Women’s Hospital,
Boston, MA, USA; 3Harvard School of Public Health, Boston, MA, USA |
| PCV15 |
TOTAL DIRECT MEDICAL
AND DRUG COSTS OF NON-ADHERENCE TO STATIN THERAPY WITHIN THE FIRST YEAR OF
TREATMENT
Peterson AM, Sanoski CA, McGhan WF, Philadelphia College of
Pharmacy, Philadelphia, PA, USA |
| PCV16 |
DIFFERENCES IN
HOSPITAL LENGTH-OF-STAY, CHARGES AND MORTALITY IN CONGESTIVE HEART FAILURE
PATIENTS
Joshi AV1, D'Souza AO2, Madhavan SS3, 1West Virginia
University/Pfizer, Morgantown, WV, USA; 2West Virginia University/Aventis,
Morgantown, WV, USA; 3West Virginia University, Morgantown, WV, USA |
| PCV17 |
COST-EFFECTIVENESS
OF RAMIPRIL (ALTACE) IN PATIENTS POST-REVASCULARIZATION
Mallick R, Fincher C, Wyeth-Ayerst Research, Collegeville, PA, USA |
| PCV18 |
OVERWEIGHT AND
OBESITY: THE COST TO SOCIETY AND THE ASSOCIATION WITH BODY MASS INDEX
Belisari A, Carruba MO, Mantovani LG, University of Milan, Milan,
Italy |
| PCV19 |
THE
COST-EFFECTIVENESS ANALYSIS OF ASPIRIN FOR PRIMARY PREVENTION OF
CARDIOVASCULAR DISEASE
Patel PA, Hay J, University of Southern California, Los Angeles, CA,
USA |
| PCV20 |
A COST-EFFECTIVENESS
ANALYSIS OF STATIN THERAPY IN A MANAGED CARE POPULATION
Bullano MF1, Willey VJ1, Cziraky MJ1, Graham L2, Corbelli JC3,
1Health Core, Newark, DE, USA; 2Pfizer, New York, NY, USA; 3Buffalo
Cardiology and Pulmonary Associates, Williamsville, NY, USA |
| PCV21 |
COST-EFFECTIVENESS
OF THE FIBRATES IN THE REDUCTION OF CORONARY HEART DISEASE EVENTS
Sterling KL, Hay JW, University of Southern California, Los Angeles,
CA, USA |
| PCV22 |
AN EVALUATION OF THE
CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING HYPERLIPIDEMIC
PATIENTS TO PREFERRED STATIN THERAPY IN THE U.S. DEPARTMENT OF DEFENSE
Omar MA , Wilson J, University of Texas at Austin, Austin, TX, USA
|
| PCV23 |
THE EFFECT OF
b-BLOCKER AND ACE INHIBITOR THERAPY ON THE RISK OF HOSPITALIZATION AND
RESOURCE UTILIZATION AMONG PATIENTS WITH CHF ENROLLED IN A MANAGED CARE
ORGANIZATION
Abarca J, Malone DC, Armstrong EP, University of Arizona, Tucson, AZ,
USA |
| PCV24 |
APPLICATION OF THE
COST OF OBESITY MODEL FOR COST BENEFIT ANALYSIS (CBA) OF SIBUTRAMINE AND
ORLISTAT: A THIRD PARTY PAYER'S PERSPECTIVE
Sankaranarayanan J, Viswanathan HN, Bharmal M, Shah B, Murawski MM,
Purdue University, West Lafayette, IN, USA |
| PCV25 |
THE ECONOMIC IMPACTS
OF TROUGH: PEAK RATIO AND LIPOPHILICITY ON COST-EFFECTIVENESS OF
ACE-INHIBITOR THERAPY FOR HYPERTENSION
Keuffel EL1, Cifaldi M2, Botteman MF3, 1HERQuLES, Abt Associates
Clinical Trials, Cambridge, MA, USA; 2Abbott Laboratories, Abbott Park, IL,
USA; 3Abt Associates Clinical Trials, Bethesda, MD, USA |
| PCV26 |
FIRST RUSSIAN
EXPERIENCE OF ASSESSING WILLINGNESS TO PAY: AVOIDING AMPUTATION IN CASE OF
CRITICAL LIMB ISCHEMIA
Avxentieva M, Vorobyov P, Derkach E, Gerasimov V, Moscow Medical
Academy, Moscow, Russia |
| PCV27 |
MODEL 100 FOR
TEMPERATURE MANAGEMENT IN OFF-PUMP CORONARY ARTERY BYPASS SURGERY
Gevirtz FO1, Kline R2, Brooks EA1, Lawten J2, Buckley AE3, Roberts
SS3, Gao X4, 1PPD Development, Inc, Morrisville, NC, USA; 2Medivance, Inc,
Louisville, CO, USA; 3PPD Development, Wilmington, NC, USA; 4PPD Inc,
Morrisville, NC, USA |
| PCV28 |
A COST ANALYSIS OF
"BRIDGING THERAPY" FOR PATIENTS REQUIRING INTERRUPTION OF CHRONIC
ANTICOAGULATION
Amorosi SL1, Thompson D1, Goldhaber SZ2, Tsilimingras K2, Fanikos J2,
Weinstein MC3, 1Innovus Research, Inc, Medford, MA, USA; 2Brigham & Women’s
Hospital, Boston, MA, USA; 3Harvard School of Public Health, Boston, MA, USA |
| PCV29 |
INFLUENCE OF
COMORBID CONDITIONS IN THE HOSPITALIZATION OF ANGINA PATIENTS
Morris L, Henderson SC, von Allmen H, Gale B, Margolis J, IMS Health,
Plymouth Meeting, PA, USA |
| PCV30 |
ECONOMIC EVALUATION
OF THREE MARKET LEADING HMG-CO-A REDUCTASE INHIBITORS
Danielson DL, University of North Carolina-Chapel Hill, Chapel Hill,
NC, USA |
| PCV31 |
COST-EFFECTIVENESS
ANALYSIS OF THE ARCTIC SUN™ MODEL 100 FOR TEMPERATURE MANAGEMENT IN OFF-PUMP
CORONARY ARTERY BYPASS SURGERY
Gevirtz FO1, Kline R2, Brooks EA1, Lawten J2, Gao X1, Roberts SS3,
Buckley AE3, 1PPD Development, Morrisville, NC, USA; 2Medivance, Inc,
Louisville, CO, USA; 3PPD Development, Willmington, NC, USA |
| PCV32 |
COST OF ILLNESS AND
RESOURCE UTILIZATION FOR PATIENTS SUFFERING MYOCARDIAL INFARCTION, WITH AND
WITHOUT DEPRESSION
Taylor AT1, Athar MM1, Maclean JR2, Waller JL2, Gottleib M3,
1University of Georgia, Augusta, GA, USA; 2Medical College of Georgia,
Augusta, GA, USA; 3Blue Cross and Blue Shield of Georgia, Atlanta, GA, USA |
|
Quality of Life Presentations |
| PCV33 |
QUALITY OF LIFE
QUESTIONNAIRES VALIDATION IN ESSENTIAL HYPERTENSIVES FROM AN ECONOMICALLY
DISADVANTAGED COMMUNITY
Golubev SA1, Mily MN2, 1Vitebsk State Medical University, Vitebsk,
Belarus; 2Vitebsk City Emergency Hospital, Vitebsk, Belarus |
|
Health Policy Presentations |
| PCV34 |
PATTERNS OF
ANTIHYPERTENSIVE DRUG UTILIZATION AND CLINIC VISITS FOR ESSENTIAL
HYPERTENSION: EVIDENCE FROM MEDICAL EXPENDITURE PANEL SURVEY, 1996
Guo D, Fu AZ, Liu GG, University of North Carolina at Chapel
Hill, Chapel Hill, NC, USA |
| PCV35 |
AN ASSESSMENT OF THE
POTENTIAL UK POPULATION OF PEOPLE WITH TYPE 2 DIABETES ELIGIBLE FOR
PROPHYLAXIS WITH RAMIPRIL TO PREVENT CARDIOVASCULAR EVENTS
Jones S1, Bowes P1, Hall E1, Connolly V1, Kelly W1, Bilous R1, Hutchings
A2, 1Middlesbrough General Hospital, Middlesbrough, UK; 2Aventis Pharma,
West Malling, UK |
| PCV36 |
MEDICATION ADHERENCE
AND HEALTH CARE UTILIZATION IN HEART FAILURE PATIENTS
Chui MA1, Murray MD2, 1Midwestern University, Glendale, AZ, USA;
2Purdue University, West Lafayette, IN, USA |
| PCV37 |
EFFECT OF
NON-ADHERENCE TO STATINS ON ASSOCIATED COST EFFECTIVENESS
Heerey AM, Barry M, National Centre for Pharmacoeconomics in Ireland,
Dublin, Ireland |
| PCV38 |
MORE MEDICATIONS AND
DISEASE STATES WERE RELATED TO AN INCREASE IN MEDICATION ADHERENCE AMONG
PATIENTS AFTER A MYOCARDIAL INFARCTION
McBurney CR1, Erickson SR2, Kline-Rogers EM2, Smith DE2, Eagle KA2,
1University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; 2University of
Michigan, Ann Arbor, MI, USA |
|
ARTHRITIS & OSTEOPOROSIS |
|
Clinical Outcomes Presentation |
| PAO1 |
CARDIORENAL EFFECTS
AND COSTS OF COX-2 INHIBITORS IN A MANAGED CARE ORGANIZATION
Yu-Isenberg KS1, Leslie RS1, Chang EY1, White TJ1, Bailey KL2,
1Prescription Solutions, Costa Mesa, CA, USA; 2Pharmacia Corporation,
Peapack, NJ, USA |
| PAO2 |
TREATMENT PATTERNS
OF CARE AND THE RISK OF SUBSEQUENT FRACTURES AMONG OSTEOPOROTIC WOMEN WITH
INCIDENT FRACTURES
Yu-Isenberg KS1, Ventura EP1, Chang EY1, White TJ1, Kemner JE2,
Ogostalick A3, 1Prescription Solutions, Costa Mesa, CA, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA; 3Eli Lilly and Company, Anaheim, CA, USA
|
|
Economic Outcomes Presentations |
| PAO3 |
MODELLED
COST-UTILITY ANALYSIS OF ROFECOXIB AND TRADITIONAL NON-STEROIDAL THERAPIES
FOR TREATMENT OF CHRONIC OSTEOARTHRITIS
Schulz M1, Noble I1, Tilden D2, Davey P2, Crowley S1, 1Merck Sharp &
Dohme (Australia), Sydney, NSW, Australia; 2M-TAG, Sydney, NSW, Australia |
| PAO4 |
COST ANALYSIS OF A
12-WEEK CYCLE OF THERAPY WITH CELECOXIB VS CONVENTIONAL NSAIDS IN PATIENTS
WITH OSTEOARTHRITIS
Chiroli S, Roggeri DP, Pharmacia Italia SpA, Milano, Italy |
| PAO5 |
AN ECONOMIC MODEL
FOR GASTROINTESTINAL RISK STRATIFICATION COMPARING COX-2 INHIBITORS TO
TRADITIONAL NSAIDS FOR ARTHRITIS TREATMENT
DeLattre ML1, Schaefer MG2, Morreale AP2, Plowman BK2, 1VA San Diego
Healthcare System/University of the Pacific, San Diego, CA, USA; 2VA San
Diego Healthcare System, San Diego, CA, USA |
| PAO6 |
COST-EFFECTIVENESS
OF BISPHOSPHONATE THERAPIES IN POST-MENOPAUSAL WOMEN: A THRESHOLD ANALYSIS
Burge RT1, Grima D2, Becker D2, Tosteson AN3, 1Procter & Gamble
Pharmaceuticals, Mason, OH, USA; 2Innovus Research Inc, Burlington, ON,
Canada; 3Dartmouth Medical School, Lebanon, NH, USA |
| PAO7 |
COST OFFSETS ARISING
FROM THE USE OF MIACALCIN: PRELIMINARY RESULTS
Latimer E1, Barbeau M2, 1Douglas Hospital Research Centre, McGill
University, Verdun, QC, Canada; 2Novartis Pharma Canada Inc, Dorval, QC,
Canada |
| PAO8 |
FIRST-YEAR COSTS
ASSOCIATED WITH NOVEL DISEASE-MODIFYING DRUGS IN THE TREATMENT OF PATIENTS
WITH RHEUMATOID ARTHRITIS
Huse D1, Doyle J2, 1PharMetrics, Inc, Watertown, MA, USA; 2Aventis
Pharmaceuticals, Parsippany, NJ, USA |
| PAO9 |
AN ECONOMIC
COMPARISON BETWEEN COX-2 INHIBITORS AND CONVENTIONAL NSAIDS IN THE TREATMENT
PAIN RELATED TO ARTHRITIS
Beard S, Gaffney L, RTI Health Solutions, Manchester, UK |
| PAO10 |
COST-EFFECTIVENESS
OF PHARMACEUTICAL TREATMENTS OF FRACTURE IN WOMEN WITH ESTABLISHED
OSTEOPOROSIS IN HONG KONG
Zhang JX, Lau E, The Chinese University of Hong Kong, Shatin, NT,
Hong Kong |
| PAO11 |
COST-EFFECTIVENESS
OF VARIOUS TREATMENT STRATEGIES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN
POLAND
Orlewska E1, Lis J2, 1Medical University of Warsaw, Warsaw, Poland;
2Eli Lilly Polska, Warsaw, Poland |
|
Quality of Life Presentations |
| PAO12 |
WEB-BASED HEALTH
STATUS ASSESSMENT OF A NATIONALLY REPRESENTATIVE SAMPLE OF ELDERLY
OSTEOARTHRITIC PATIENTS
Madnani DM1, Nayak RA1, Ward J2, 1St. John's University, Jamaica, NY,
USA; 2Knowledge Networks Inc, New York, NY, USA |
| PAO13 |
VALIDATION OF A
PATIENT QUESTIONNAIRE TO ASSESS OSTEOPOROSIS-RELATED ATTITUDES, KNOWLEDGE
AND BEHAVIOR
Brenneman SK1, Blau EM2, Chen YT1, Abbott TA1, 1Merck & Co., Inc,
West Point, PA, USA; 2Kaiser Permanente - Southern California, San Diego,
CA, USA |
| PAO14 |
APPLICATION OF RASCH
ANALYSIS IN COMPARISON OF SELF-ASSESSED HEALTH STATUS ACROSS TWO ARTHRITIS
CONDITIONS USING A GENERIC HEALTH STATUS SURVEY
Dalal M, Basu S, Smith E, University of Illinois at Chicago, Chicago,
IL, USA |
| PAO15 |
IMPACT OF ETANERCEPT
FOR RHEUMATOID ARTHRITIS (RA) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND
FUNCTIONAL STATUS IN A NATURALISTIC SETTING
Kamikawa BF, Wanke LA, Immunex Corporation, Seattle,
WA, USA |
| PAO16 |
RISK OF CLINICAL
DEPRESSION IN ARTHRITIS: A WEB-BASED CO-ADMINISTRATION OF CESD-20 AND SF-36
TO A NATIONALLY REPRESENTATIVE ELDERLY SAMPLE
Nayak RA1, Madnani DM1, Ward J2, 1St. John's University,
Jamaica, NY, USA; 2Knowledge Networks Inc, New York, NY, USA |
| PAO17 |
STRENGTHS AND
LIMITATIONS OF FUNCTIONAL HEALTH STATUS INSTRUMENTS FOR OSTEOARTHRITIS
Kelleher JK1, Stephens JM2, Haider S3, Pashos CL1, 1Abt Associates
Clinical Trials, Cambridge, MA, USA; 2Abt Associates Clinical Trials,
Bethesda, MD, USA; 3Pfizer, Inc, Groton, CT, USA |
|
Health Policy Presentations |
| PAO18 |
CALCIUM
SUPPLEMENTATION AND REDUCTION IN ASSOCIATED FRACTURES IN MEDICAID
OSTEOPOROSIS PATIENTS
Dodd MA, Shah BM, Gupchup GV, Anderson JR, The University of New
Mexico, Albuquerque, NM, USA |
| PAO19 |
UTILIZATION
CHARACTERISTICS OF COX-2 INHIBITORS IN A LARGE MANAGED CARE HEALTH PLAN
Yu W1, Kiang G1, Etemad LR2, 1WellPoint Pharmacy Management, West
Hills, CA, USA; 2University of Southern California, Los Angeles, CA, USA |
| PAO20 |
TRENDS OF
ANTIRESORPTIVE THERAPIES USE AMONG WOMEN WITH PREVIOUS OSTEOPOROTIC FRACTURE
Perreault S1, Desgagné A1, Boucher JM1, Blais L2, Le Lorier J1,
Ste-Marie LG3, 1Montreal University, Montreal, QC, Canada; 2Montreal
University, Montreal, QC, Canada; 3University of Montreal, Montreal, QC,
Canada |
| PAO21 |
MISSED OPPORTUNITIES
IN PHARMACEUTICAL TREATMENT OF OSTEOPOROSIS IN POST-FRACTURE WOMEN
Wall MJ1, Beilfuss CD1, Graff JS1, McBurney CR1, Fendrick AM2,
1University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; 2University of
Michigan, Ann Arbor, MI, USA |
| PAO22 |
REFILL ADHERENCE IN
OSTEOPOROTIC WOMEN WITH PRIMARY AND SECONDARY FRACTURE PREVENTION
Beilfuss CD1, Wall MJ1, Graff JS1, McBurney CR1, Fendrick AM2,
1University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; 2University of
Michigan, Ann Arbor, MI, USA |
|
ASTHMA & RESPIRATORY DISEASES/DISORDERS |
|
Clinical Outcomes Presentations |
| PAR1 |
ANALYSIS OF NASAL
STEROID DOSING PATTERNS IN A LARGE SAMPLE FROM A PRESCRIPTION DATABASE
Moore E, Dept. of Defense Pharmacoeconomic Center, Fort Sam Houston,
TX, USA |
|
Economic Outcomes Presentations |
| PAR2 |
PREVALENCE AND
CORRELATES OF REDUCED PRODUCTIVITY ASSOCIATED WITH ALLERGIC RHINITIS IN THE
WORKPLACE
Ershoff D1, Sullivan S2, Armstrong DS3, 1Integrated Therapeutics
Group, Tarzana, CA, USA; 2Institute for Health and Productivity Management,
Scottsdale, AZ, USA; 3Integrated Therapeutics Group, La Verne, CA, USA |
| PAR3 |
COSTS OF ALLERGIC
RHINITIS IN THE U.S
Law AW, Reed SD, Schulman KA, Duke Clinical Research Institute,
Durham, NC, USA |
| PAR4 |
ESTIMATION AND
COMPARISON OF LOSS IN PRODUCTIVITY BY THE HUMAN CAPITAL AND FRICTION COST
APPROACH IN PATIENTS WITH ASTHMA
Sarawate C, University of Illinois at Chicago, Chicago, IL, USA |
| PAR5 |
HEALTH CARE
RESOURCES UTILIZATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Lachaine J1, Bradley-Kennedy C2, 1University of Montreal, Montreal,
QC, Canada; 2Boehringer Ingelheim Canada Ltd, Burlington, QC, Canada |
| PAR6 |
ESTABLISHING THE
RELIABILITY OF EVIDENCE FOR THE SIGNIFICANT IMPACT OF ALLERGIC RHINITIS ON
HEALTH RELATED COSTS
Sullivan S1, Armstrong DS2, Ershoff D3, 1Institute for Health and
Productivity Management, Scottsdale, AZ, USA; 2Integrated Therapeutics
Group, La Verne, CA, USA; 3Integrated Therapeutics Group, Tarzana, CA, USA |
| PAR7 |
ECONOMIC
CONSEQUENCES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A NATIONAL SAMPLE
OF US ADULTS
Sendersky V1, Law AW2, Gause D3, Sung J3, 1Duke University/Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA; 2Duke University,
Durham, NC, USA; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA |
| PAR8 |
COSTS AND BENEFITS
ASSOCIATED WITH INITIATION OF FLUTICASONE VERSUS MONTELUKAST AS CONTROLLER
THERAPY IN A MEDICAID ASTHMATIC POPULATION
Balkrishnan R1, Camacho F1, Schechter MS1, Pleasants RA2, Bowton DL1,
1Wake Forest University School of Medicine, Winston-Salem, NC, USA;
2Campbell University School of Pharmacy, Buies Creek, NC, USA |
| PAR9 |
COSTS AND BENEFITS
ASSOCIATED WITH ADDITION OF SALMETEROL VERSUS MONTELUKAST TO INHALED
CORTICOSTEROID THERAPY IN A MEDICAID ASTHMATIC POPULATION
Balkrishnan R1, Camacho F1, Schechter MS1, Pleasants RA2, Bowton DL1,
1Wake Forest University School of Medicine, Winston-Salem, NC, USA;
2Campbell University School of Pharmacy, Buies Creek, NC, USA |
| PAR10 |
RESOURCE UTILIZATION
FOR INPATIENT ASTHMA CARE IN CHILDREN AND ADULTS: AN ANALYSIS OF HCUP DATA
Hassan MK, Amonkar MM, West Virginia University, Morgantown, WV, USA |
| PAR11 |
COST-UTILITY
ANALYSIS OF MIDDLE SEVERE ASTHMA WITH SODIUM CROMOGLYCATE AND SODIUM
NEDOCROMIL
Prosekova E1, Geltzer B1, Dercach V2, Bogdanovskiy P1, Frisman M1,
1Vladivostok State Medical University, Vladivostok, Russia; 2Child's
Municipal Asthma-centre, Vladivostok, Russia |
| PAR12 |
ESTIMATES OF THE
COST OF ASTHMA IN A EMPLOYER POPULATION
Atherly AJ1, Williams SG2, 1Emory University / Centers for Disease
Control, Atlanta, GA, USA; 2Centers for Disease Control, Atlanta, GA, USA |
| PAR13 |
THE COST OF ASTHMA
IN CATALONIA: A DESCRIPTIVE AND MODELLING APPROACH
Rovira J1, Abbas I2, Hermida H2, 1The World Bank, Washington, DC,
USA; 2SOIKOS, Barcelona, Spain |
| PAR14 |
USE OF AN
INTERACTIVE VOICE RESPONSE SYSTEM (IVRS) FOR LONG-TERM RESOURCE USE DATA
COLLECTION
O'Brien J, Lordan N, Ward A, Caro Research Institute, Concord, MA,
USA |
| PAR15 |
IMPACT OF ALLERGY
AND ASTHMA BOTH SEPARATELY AND CONCOMITANTLY ON LOST HOURS FROM WORK
Armstrong DS1, Ershoff D2, Sullivan S3, 1Integrated Therapeutics
Group, La Verne, CA, USA; 2Integrated Therapeutics Group, Tarzana, CA, USA;
3Institute for Health and Productivity Management, Scottsdale, AZ, USA |
|
Quality of Life Presentations |
| PAR16 |
CULTURAL ADAPTATION
AND VALIDATION OF CHILDHOOD ASTHMA QUESTIONNAIRE VERSION B (CAQ-B) FOR
SINGAPORE CHILDREN
Chong LY1, Chay OM2, Goh A2, Seng YC2, Li SC1, 1National University
of Singapore, Department of Pharmacy, Singapore, Singapore; 2KK Women's and
Children’s Hospital, Singapore, Singapore |
|
Health Policy Presentations |
| PAR17 |
CLINICAL, PUBLIC
HEALTH, AND ECONOMIC ISSUES ASSOCIATED WITH SWITCHING SECOND-GENERATION
ANTIHISTAMINES FROM PRESCRIPTION TO OVER-THE-COUNTER
Prasad M, Shih YCT, Luce BR, MEDTAP International Inc, Bethesda, MD,
USA |
| PAR18 |
PREGNANCY OUTCOMES
IN WOMEN TAKING ANTI-ASTHMATIC MEDICATIONS IN THE GEORGIA MEDICAID
POPULATION
Joseph GJ1, Kotzan JA2, Wade WE3, 1Hines VA Hospital, Hines, IL, USA;
2University of Georgia, Athens, GA, USA; 3University of Georgia College of
Pharmacy, Athens, GA, USA |
|
CANCER |
|
Clinical Outcomes Issues |
| PCN1 |
LONG-TERM BENEFITS
OF CHEMOPREVENTIVE TAMOXIFEN AND ROUTINE MAMMOGRAPHY SCREENING IN WOMEN WHO
ARE AT INCREASED RISK OF BREAST CANCER
Borker R, Madhavan S, Simon K, Higa G, Amonkar M, Scott V, West
Virginia University, Morgantown, WV, USA |
| PCN2 |
AN INTERIM COST AND
OUTCOME COMPARISON ALONGSIDE A PROSPECTIVE RANDOMIZED CLINICAL TRIAL
COMPARING EARLY INTENSIFICATION WITH BONE MARROW TRANSPLANTATION (BMT) TO
CONVENTIONAL DOSE CHEMOTHERAPY FOR PREVIOUSLY UNTREATED PATIENTS WITH
AGGRESSIVE NON-HODGKIN'S LYMPHOMA
Adamus AT, Arbuckle RB, King KM, Rodriguez MA, University of Texas
M.D. Anderson Cancer Center, Houston, TX, USA |
| PCN3 |
COLLECTION OF
INFECTIOUS DISEASE AND ECONOMIC OUTCOMES FOR NON-HODGKIN'S LYMPHOMA AND
MULTIPLE MYELOMA PATIENTS ADMITTED FOR INFECTIOUS COMPLICATIONS UTILIZING A
PALMTM HANDHELD
King KM, Wood AM, Arbuckle RB, Adamus AT, Hagemeister FB, University
of Texas M.D. Anderson Cancer Center, Houston, TX, USA |
|
Economic Outcomes Presentations |
| PCN4 |
RETROSPECTIVE COST
ANALYSIS OF GEMZAR™ IN COMBINATION WITH CISPLATIN IN NON-SMALL CELL LUNG
CANCER COMPARED TO OTHER COMBINATION THERAPIES
IN GERMANY
Kielhorn A1, Maniadakis N1, Aristides M2, Lees M3, Tilden D2, 1Eli
Lilly, Windlesham, Surrey, UK; 2Medical Technology Assessment Group, London,
UK; 3Medical Technology Assessment Group, Chatswood West, NSW, Australia
|
| PCN5 |
PROSPECTIVE HEALTH
ECONOMIC EVALUATION OF MEDICAL CARE FOR PATIENTS WITH MALIGNANT LYMPHOMAS IN
GERMANY: FIRST RESULTS
Reis A1, Gandjour A2, Paulus U1, Franklin J1, Lauterbach K2, Diehl
V1, Walshe R1, 1First Department of Internal Medicine, University of
Cologne, Cologne, Germany; 2Institute of Health Economics and Clinical
Epidemiology, University of Cologne, Cologne, Germany |
| PCN6 |
FAMILY CAREGIVING
COSTS FOR CANCER PATIENTS: A MULTI-EMPLOYER ANALYSIS
Cremieux P1, Duh MS1, Birnbaum H2, Blasi M2, Gardner H3, 1Analysis
Group/Economics, Cambridge, MA, USA; 2Ortho Biotech Products, LP, Raritan,
NJ, USA; 3Options and Choices Inc, Cheyenne, WY, USA |
| PCN7 |
COLORECTAL CANCER
SCREENING: A COST-EFFECTIVENESS MODEL COMPARING VIRTUAL COLONOSCOPY AND
CONVENTIONAL COLONOSCOPY
Patel BV, Hay JW, University of Southern California, Los Angeles, CA,
USA |
| PCN8 |
COST-EFFECTIVENESS
ANALYSIS OF LHRH AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER
Iskedjian M1, Hemels M2, Iscoe N3, Fleshner N4, Einarson T2,
1Pharmideas Research and Consulting Inc, Oakville, ON, Canada; 2University
of Toronto, Toronto, ON, Canada; 3Toronto-Sunnybrook Regional Cancer Centre,
Toronto, ON, Canada; 4Sunnybrook and Women's Health Sciences Center,
Toronto, ON, Canada |
| PCN9 |
PHARMACOECONOMIC
ANALYSES OF AVAILABLE CHEMOTHERAPEUTIC AGENTS FOR THE MANAGEMENT OF ADVANCED
COLORECTAL CANCER
Kamal-Bahl S1, Doshi JA1, Grossman P2, 1University of Maryland,
Baltimore, MD, USA; 2Bristol-Myers Squibb Company, Wallingford, CT, USA |
| PCN10 |
WITHDRAWN |
| PCN11 |
COSTS AND
CHARACTERISTICS OF PATIENTS WHO UNDERGO BONE MARROW TRANSPLANT (BMT)
Friedman JY1, Reed SD1, Glendenning A2, Schulman KA1, 1Duke Clinical
Research Institute, Durham, NC, USA; 2Novartis Pharmaceuticals, East
Hanover, NJ, USA |
| PCN12 |
AN UPDATED RISK
THRESHOLD MODEL FOR G-CSF PROPHYLAXIS USE IN CANCER CHEMOTHERAPY:
INCORPORATION OF PATIENT OUT-OF-POCKET AND INDIRECT COSTS
Cosler LE1, Agboola O2, Calhoun EA3, Lyman GH2, 1Albany College of
Pharmacy, Albany, NY, USA; 2Albany Medical Center, Albany, NY, USA;
3Northwestern University Medical School, Chicago, IL, USA |
| PCN13 |
COST-EFFECTIVENESS
OF RITUXIMAB IN DIFFUSE LARGE B CELL LYMPHOMA
Best JH1, Hornberger J2, Omnes LF3, Coiffier B4, 1Acumen, LLC,
Burlingame, CA, USA; 2Acumen, LLC and Stanford University School of
Medicine, Burlingame, CA, USA; 3Annie Chicoye Economics, Neuilly Sur Seine,
France; 4Centre Hospitalier Lyon Sud, Pierre Bénite, France |
| PCN14 |
GENDER, FAMILY
HISTORY AND OPTIMAL LIFETIME SCREENING PROGRAMS FOR COLORECTAL CANCER: A
MODEL BASED ECONOMIC EVALUATION
Sahmoun A, Balkrishnan R, Wake Forest University School of Medicine,
Winston-Salem, NC, USA |
| PCN15 |
CLINICAL AND
ECONOMIC OUTCOMES ASSOCIATED WITH METASTATIC COLORECTAL CANCER IN MANAGED
CARE POPULATIONS: CAPECITABINE (XELODA®) VERSUS COMPARISON THERAPIES
Baran RW1, Dupere WM2, Taylor K2, Miao S3, Joseph J3, Ilersich L4,
Pandey L3, 1Roche Laboratories, Inc, Nutley, NJ, USA; 2Lifemetrix, McLean,
VA, USA; 3University of the Sciences in Philadelphia, Philadelphia, PA, USA;
4Hoffman La Roche Ltd, Mississauga, ON, Canada |
| PCN16 |
EXCESS MORTALITY AND
COSTS ASSOCIATED WITH SERIOUS FUNGAL INFECTIONS AMONG ELDERLY CANCER
PATIENTS: FINDINGS FROM LINKED SEER-MEDICARE DATA
Menzin J1, Lang K1, Friedman M1, Dixon D1, Marton J2, Wilson J2,
1Boston Health Economics, Waltham, MA, USA; 2Pfizer, Inc, New York, NY, USA |
|
Quality of Life Presentations |
| PCN17 |
SIDE EFFECTS OF
CHEMOTHERAPY AMONG PATIENTS WITH OVARIAN CANCER: IMPLICATIONS FOR QUALITY OF
LIFE
Lewis BE1, Silberman C2, Janine M3, Heyes A4, 1Focus Managed
Research, Worcester, MA, USA; 2AstraZeneca, Wilmington, DE, USA; 3Focus
Managed Research, Longmeadow, MA, USA; 4AstraZeneca UK Limited, Macclesfield,
UK |
| PCN18 |
AN APPRAISAL OF
TREATMENT SATISFACTION AND PATIENT PREFERENCE ASSESSMENTS IN PATIENTS
DIAGNOSED WITH CANCER
McBurney CR1, Coombs JH2, Hsu MA3, Abetz L4, Keininger D5,
Copley-Merriman C2, 1University of Michigan and Pfizer Inc, Ann Arbor, MI,
USA; 2Pfizer Inc, Ann Arbor, MI, USA; 3Pfizer Inc, Groton, CT, USA; 4Mapi
Values, Cheshire, UK; 5Mapi Values, Boston, MA, USA |
| PCN19 |
USE OF THE EUROQOL
VISUAL ANALOGUE SCALE IN ASSESSING LONGITUDINAL CHANGES IN QUALITY OF LIFE
IN CANCER PATIENTS: A COMPARISON WITH SUBSCALES OF THE MEDICAL OUTCOMES
SURVEY SHORT FORM-36
Castel LD1, Reed SD1, Weinfurt KP1, Li Y1, Law AW1, Meropol NJ2,
Schulman KA1, 1Duke Clinical Research Institute, Durham, NC, USA; 2Fox Chase
Cancer Center, Philadelphia, PA, USA |
|
Health Policy Presentations |
| PCN20 |
ASSOCIATION OF
INSURANCE COVERAGE AND EPIDEMIOLOGICAL RISK FACTORS ON GASTRIC CANCER
SURGERY
Wu W1, Donato B2, Grossman P2, Hines P1, 1Bristol-Myers Squibb
Company, Princeton, NJ, USA; 2Bristol-Myers Squibb Company, Wallingford, CT,
USA |
|
DIABETES |
|
Clinical Outcomes Presentations |
| PDB1 |
WITHDRAWN |
| PDB2 |
A RETROSPECTIVE
COHORT STUDY OF DIABETES MELLITUS AND ANTIPSYCHOTIC TREATMENT IN THE UNITED
KINGDOM
Cavazzoni P1, Hornbuckle K1, Wu J2, Breier A1, Kotsanos J1, Holman
R3, 1Lilly Research Laboratories, Indianapolis, IN, USA; 2University of
Michigan, Ann Arbor, MI, USA; 3University of Oxford, Oxford, Oxford, UK |
| PDB3 |
IMPROVEMENTS IN LIFE
EXPECTANCY WITH LIFESTYLE CHANGES OR METFORMIN IN OVERWEIGHT, GLUCOSE
INTOLERANT PATIENTS: A MODELING STUDY OF THE LONG-TERM IMPLICATIONS OF THE
DIABETES PREVENTION PROGRAM
Palmer AJ1, Roze S, 1CORE Center for Outcomes Research, Basel, BS,
Switzerland |
| PDB4 |
OUTCOMES WITH
ROSIGLITAZONE IN CLINICAL PRACTICE
McGibbon A1, Tuttle J1, Kim T2, Ur E1, 1Dalhousie University,
Halifax, NS, Canada; 2GlaxoSmithKline, Mississauga, ON, Canada |
|
Economic Outcomes Presentations |
| PDB5 |
THE ECONOMIC VALUE
OF NON-DIHYDROPYRIDINE VS. DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER/ACE
INHIBITOR COMBINATIONS IN PATIENTS WITH TYPE-II DIABETES
Keuffel EL1, Cifaldi M2, Botteman MF3, 1HERQuLES, Abt Associates
Clinical Trials, Cambridge, MA, USA; 2Abbott Laboratories, Abbott Park, IL,
USA; 3Abt Associates Clinical Trials, Bethesda, MD, USA |
| PDB6 |
PREVENTION OF TYPE 2
DIABETES IN THE USA: COST-EFFECTIVENESS ISSUES
Palmer AJ, Roze S, CORE Center for Outcomes Research, Basel, BS,
Switzerland |
| PDB7 |
FINANCIAL IMPACT OF
IMPROVED DIABETES MANAGEMENT THROUGH BLOOD KETONE TESTING AND OPTIMIZED
GLYCEMIC CONTROL
Luo MP1, Rao S2, Ashraf T1, 1Abbott Laboratories, Abbott Park, IL,
USA; 2Abbott Laboratories, Bedford, MA, USA |
| PDB8 |
ECONOMIC COMPARISON
OF SIX FIRST-LINE DRUG STRATEGIES IN TYPE 2 DIABETES USING A MONTE CARLO
SIMULATION MODEL
Stephens JM1, Ramsdell JW2, Braunstein S3, Bell CF1, Botteman MF1,
Brandt S1, Devine ST4, 1Abt Associates Clinical Trials, Bethesda, MD, USA;
2University of California San Diego Medical Center, San Diego, CA, USA;
3University of Pennsylvania Health System, Philadelphia, PA, USA; 4Pfizer
Inc, New York, NY, USA |
| PDB9 |
A RETROSPECTIVE
ANALYSIS OF SHORT-TERM COSTS AND UTLIZATION ASSOCIATED WITH GLYCEMIC CONTROL
AMONG TYPE2 DIABETIC PATIENTS WITHIN A MANAGED CARE ORGANIZATION
Chen KS, Melikian CA, Chang EY, White TJ, Prescription Solutions,
Costa Mesa, CA, USA |
| PDB10 |
INCIDENCE,
MANAGEMENT AND COST OF CARDIO-VASCULAR AND RENAL COMPLICATIONS IN FRENCH
TYPE 2 DIABETIC PATIENTS
Fagnani F1, Souchet T2, Labed D3, 1CEMKA, Bourg la Reine, France;
2Merck Sharp & Dohme - Chibret, Paris, France; 3IMS - Health, Nanterre,
France |
| PDB11 |
HEALTH SERVICES COST
AND UTILIZATION COMPARISONS AMONG LISPRO AND NON-LISPRO REGULAR INSULIN
USERS
Hall JA1, Summers KH2, Obenchain RL2, 1Ingenix Pharmaceutical
Services, Eden Prairie, MN, USA; 2Eli Lilly & Company, Indianapolis, IN, USA |
|
Quality of Life Presentations |
| PDB12 |
FACTORS PREDICTING
SELF-RATED HEALTH AND PATIENT SATISFACTION IN A MANAGED CARE DIABETES
POPULATION
Nau DP, Kumar RN, University of Michigan, Ann Arbor, MI, USA |
|
Health Policy Presentations |
| PDB13 |
TRENDS IN INSULIN
THERAPY FOR TREATMENT OF TYPE-2 DIABETES MELLITUS
Conklin JE1, Neslusan CA2, Cohen F3, Song X1, 1The MEDSTAT Group,
Santa Barbara, CA, USA; 2Pharmaceuticals Group Strategic Marketing, Raritan,
NJ, USA; 3RW Johnson Pharmaceutical Research Institute, Raritan, NJ, USA |
| PDB14 |
PATIENT’S
PERSPECTIVE OF HYPOGLYCEMIA AS AN ADVERSE EFFECT OF ORAL ANTIDIABETIC
MEDICATIONS
Salas M1, Caro JJ1, Sung J2, Garfield F1, 1Caro Research Institute,
|
| PDB15 |
USING SURVIVAL MODELS TO PREDICT
THE START OF INSULIN
IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Rosenblum MS1, Dirani R2, Bowman A3, 1Integrail, Latham, NY, USA;
2Aventis Pharmaceuticals, Bridgewater, NJ, USA; 3Union College,
Schenectady, NY, USA |
|
